Radiation therapy is the most commonly used initial treatment for low-grade gliomas. The purpose of this study is to determine if adding the drug temozolomide to radiation is more effective than radiation therapy alone in patients with low-grade gliomas that are causing symptoms or are continuing to grow.
Patients will be randomly assigned to receive radiation therapy with or without temozolomide. Temozolomide is approved for treating high-grade gliomas and is taken by mouth. Patients who receive temozolomide will take the medication during the period they are receiving radiation therapy as well as after radiation is completed.